HRR alterations, especially those in BRCA1, BRCA2, and PALB2 have been associated with sensitivity to platinum agents in ovarian and breast cancer.11,12 Our findings are consistent with a small study of 26 patients harboring germline mutations in BRCA1, BRCA2, or PALB2 which identified a higher response rate and rwPFS on FOLFIRINOX relative to a wildtype control group.3 This evidence concerns the gene BRCA1 and breast cancer.